Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce W Bode

Showing results (51-60 of 128) with videos related to

Pageof 13
Sort By:
Diabetes Care|July 27, 2005
Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trialRalph A DeFronzo, Richard M Bergenstal, William T Cefalu, et al.
Diabetes, Obesity & Metabolism|January 10, 2018
Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trialChantal Mathieu, Bruce W Bode, Edward Franek, et al.
JAMA|September 16, 2016
Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 DiabetesRichard M Bergenstal, Satish Garg, Stuart A Weinzimer, et al.
Diabetes Care|March 1, 2005
Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSIIIrl B Hirsch, Bruce W Bode, Satish Garg, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 29, 2012
Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trialSatish K Garg, Emily G Moser, Bruce W Bode, et al.
Diabetes Care|May 10, 2017
Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 TrialKeith Bowering, Christopher Case, John Harvey, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 13, 2016
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical TrialSultan Linjawi, Bruce W Bode, Louis B Chaykin, et al.
Diabetes Care|May 12, 2019
Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 TrialBruce W Bode, Violeta Iotova, Margarita Kovarenko, et al.
BMJ Open Diabetes Research & Care|December 15, 2020
Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trialJohn B Buse, Bruce W Bode, Ann Mertens, et al.
The Diabetes Educator|April 9, 2016
Improving Patient Experience With Insulin Infusion Sets: Practical Guidelines and Future DirectionsAlison B Evert, Bruce W Bode, Bruce A Buckingham, et al.
Pageof 13

Showing results (51-60 of 128) with videos related to

Sort By:
Pageof 13
Diabetes Care|July 27, 2005
Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trialRalph A DeFronzo, Richard M Bergenstal, William T Cefalu, et al.
Diabetes, Obesity & Metabolism|January 10, 2018
Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trialChantal Mathieu, Bruce W Bode, Edward Franek, et al.
JAMA|September 16, 2016
Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 DiabetesRichard M Bergenstal, Satish Garg, Stuart A Weinzimer, et al.
Diabetes Care|March 1, 2005
Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSIIIrl B Hirsch, Bruce W Bode, Satish Garg, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 29, 2012
Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trialSatish K Garg, Emily G Moser, Bruce W Bode, et al.
Diabetes Care|May 10, 2017
Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 TrialKeith Bowering, Christopher Case, John Harvey, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 13, 2016
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical TrialSultan Linjawi, Bruce W Bode, Louis B Chaykin, et al.
Diabetes Care|May 12, 2019
Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 TrialBruce W Bode, Violeta Iotova, Margarita Kovarenko, et al.
BMJ Open Diabetes Research & Care|December 15, 2020
Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trialJohn B Buse, Bruce W Bode, Ann Mertens, et al.
The Diabetes Educator|April 9, 2016
Improving Patient Experience With Insulin Infusion Sets: Practical Guidelines and Future DirectionsAlison B Evert, Bruce W Bode, Bruce A Buckingham, et al.
Pageof 13